Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

One Nucleus

  1. Events
  2. Organisers
  3. One Nucleus
Events from this organiser
Today

ON Helix 2025

ON Helix 2025 will address key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools [...]

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2025 | Hlx Life Sciences

Site by theLEAP

Go to Top